The immunobiology of toll-like receptor 4 agonists: From endotoxin tolerance to immunoadjuvants

Shock

Volumn 40, Issue 6, 2013, Pages 451-462

  Bohannon, Julia K ^a   Hernandez, Antonio ^a   Enkhbaatar, Perenlei ^b   Adams, William L ^a,c   Sherwood, Edward R ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

adjuvant; Endotoxin; innate immunity; lipid A; MyD88; TLR4; TRIF

Indexed keywords

ENDOTOXIN; GLUCOSAMINE DERIVATIVE; I KAPPA B ALPHA; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 3; LIPID A; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHORYL LIPID A; PROTEIN P50; SUPPRESSOR OF CYTOKINE SIGNALING 1; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR AGONIST; TRANSCRIPTION FACTOR RELB;

B LYMPHOCYTE ACTIVATION; CROSS TOLERANCE; DIMERIZATION; DRUG EFFICACY; DRUG SAFETY; ESCHERICHIA COLI; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOBIOLOGY; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; MOLECULAR RECOGNITION; NONHUMAN; OLIGOMERIZATION; PROTEIN ANALYSIS; PROTEIN CONFORMATION; REVIEW; SALMONELLA; SIGNAL TRANSDUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BACTERIAL INFECTIONS; CYTOKINES; ENDOTOXINS; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; LIPOPOLYSACCHARIDES; TOLL-LIKE RECEPTOR 4;

EID: 84888104327     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0000000000000042     Document Type: Review

References (117)

1. Schweizer HP: Understanding efflux in gram-negative bacteria: opportunities for drug discovery. Expert Opin Drug Discov 7(7):633-642, 2012.
2. Schmidt H, Hansen G, Singh S, Hanuszkiewicz A, Lindner B, Fukase K, Woodard RW, Holst O, Hilgenfeld R, Mamat U, et al. : Structural and mechanistic analysis of the membrane-embedded glycosyltransferase WaaA required for lipopolysaccharide synthesis. Proc Natl Acad Sci U S A. 2012;109(16):6253-8. Epub 2012/04/05. doi: 10. 1073/pnas. 1119894109. PubMed PMID: 22474366; PubMed Central PMCID: PMC3341020.
3. Kalis C, Kanzler B, Lembo A, Poltorak A, Galanos C, Freudenberg MA: Tolllike receptor 4 expression levels determine the degree of LPS-susceptibility in mice. Eur J Immunol 33(3):798-805, 2003.
4. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO: The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458(7242): 1191-1195, 2009.
5. Asai Y, Hashimoto M, Fletcher HM, Miyake K, Akira S, Ogawa T: Lipopolysaccharide preparation extracted from Porphyromonas gingivalis lipoproteindeficient mutant shows a marked decrease in Toll-like receptor 2-mediated signaling. Infect Immun 73(4):2157-2163, 2005.
6. Namas R, Zamora R, An G, Doyle J, Dick TE, Jacono FJ, Androulakis IP, Nieman GF, Chang S, et al. : Something old, something new, and a systems view. J Crit Care. 2012;27(3):314 e1-11. Epub 2011/07/30. doi: 10. 1016/j. jcrc. 2011. 05. 025. PubMed PMID: 21798705; PubMed Central PMCID: PMC3206132.
7. Vandenbon A, Teraguchi S, Akira S, Takeda K, Standley DM: Systems biology approaches to Toll-like receptor signaling. Wiley Interdiscip Rev Syst Biol Med 4(5):497-507, 2012.
8. Dauphinee SM, Karsan A: Lipopolysaccharide signaling in endothelial cells. Lab Invest 86(1):9-22, 2006.
9. Carpenter S, O'Neill LA: Recent insights into the structure of Toll-like receptors and post-translational modifications of their associated signalling proteins. Biochem J 422(1):1-10, 2009.
10. Ebong SJ, Goyert SM, Nemzek JA, Kim J, Bolgos GL, Remick DG: Critical role of CD14 for production of proinflammatory cytokines and cytokine inhibitors during sepsis with failure to alter morbidity or mortality. Infect Immun 69(4):2099-2106, 2001.
11. Casella CR, Mitchell TC: Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 65(20): 3231-3240, 2008.
12. Kawai T, Akira S: Toll-like receptor downstream signaling. Arthritis Res Ther 7(1):12-19, 2005.
13. Akira S: TLR signaling. Curr Top Microbiol Immunol 311:1-16, 2006.
14. Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S, Janeway CA Jr., MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell. 1998;2(2):253-258. Epub 1998/09/12. PubMed PMID: 9734363.
15. Li X, Commane M, Jiang Z, Stark GR: IL-1Yinduced NFkappa B and c-Jun N-terminal kinase (JNK) activation diverge at IL-1 receptorYassociated kinase (IRAK). Proc Natl Acad Sci U S A 98(8):4461-4465, 2001.
16. Akira S, Sato S: Toll-like receptors and their signaling mechanisms. Scand J Infect Dis 35(9):555-562, 2003.
17. Aksoy E, Taboubi S, Torres D, Delbauve S, Hachani A, Whitehead MA, Pearce WP, Berenjeno IM, Nock G, Filoux A, et al. : The p110delta isoform of the kinase PI(3)K controls the subcellular compartmentalization of TLR4 signaling and protects from endotoxic shock. Nat Immunol. 2012;13(11):1045-1054. Epub 2012/10/02. doi: 10. 1038/ni. 2426. PubMed PMID: 23023391.
18. Kagan JC, Su T, Horng T, Chow A, Akira S, Medzhitov R: TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat Immunol 9(4):361-368, 2008.
19. Jiang Z, Mak TW, Sen G, Li X: Toll-like receptor 3Ymediated activation of NF-kappaB and IRF3 diverges at TollYIL-1 receptor domain-containing adapter inducing IFN-beta. Proc Natl Acad Sci U S A 101(10):3533-3538, 2004.
20. Husebye H, Halaas O, Stenmark H, Tunheim G, Sandanger O, Bogen B, Brech A, Latz E, Espevik T. Endocytic pathways regulate Toll-like receptor 4 signaling and link innate and adaptive immunity. EMBO J. 2006 25(4):683-692. Epub 2006/02/10. doi: 10. 1038/sj. emboj. 7600991. PubMed PMID: 16467847; PubMed Central PMCID: PMC1383569.
21. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K, et al. : Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science. 2003;301(5633):640-643. Epub 2003/07/12. doi: 10. 1126/science. 1087262. PubMed PMID: 12855817.
22. Needham BD, Carroll SM, Giles DK, Georgiou G, Whiteley M, Trent MS: Modulating the innate immune response by combinatorial engineering of endotoxin. Proc Natl Acad Sci U S A 110(4):1464-1469, 2013.
23. Raetz CR, Guan Z, Ingram BO, Six DA, Song F, Wang X, Zhao J. Discovery of new biosynthetic pathways: the lipid A story. J Lipid Res. 2009;(Suppl 50): S103YS108. Epub 2008/11/01. doi: 10. 1194/jlr. R800060-JLR200. PubMed PMID: 18974037; PubMed Central PMCID: PMC2674688.
24. Akira S: Toll-like receptors: lessons from knockout mice. Biochem Soc Trans 28(5):551-556, 2000.
25. Bolz DD, Sundsbak RS, Ma Y, Akira S, Weis JH, Schwan TG, Weis JJ. Dual role of MyD88 in rapid clearance of relapsing fever Borrelia spp. Infect Immun. 2006;74(12):6750-6760. Epub 2006/10/13. doi: 10. 1128/IAI. 01160-06. PubMed PMID: 17030581; PubMed Central PMCID: PMC1698049.
26. Roger T, Froidevaux C, Le Roy D, ReymondMK, Chanson AL, Mauri D, Burns K, Riederer BM, Akira S, Calandra T. Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4. Proc Natl Acad Sci U S A. 2009; 106(7):2348-2352. Epub 2009/02/03. doi: 10. 1073/pnas. 0808146106. PubMed PMID: 19181857; PubMed Central PMCID: PMC2650125.
27. Takeda K, Akira S: TLR signaling pathways. Semin Immunol 16(1):3-9, 2004.
28. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC: The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316(5831):1628-1632, 2007.
29. Cekic C, Casella CR, Eaves CA, Matsuzawa A, Ichijo H, Mitchell TC: Selective activation of the p38 MAPK pathway by synthetic monophosphoryl lipid A. J Biol Chem 84(46):31982-31991, 2009.
30. Pfaar O, Cazan D, Klimek L, Larenas-Linnemann D, Calderon MA: Adjuvants for immunotherapy. Curr Opin Allergy Clin Immunol 12(6):648-657, 2012.
31. AstizME, Rackow EC, Still JG, Howell ST, Cato A, Von Eschen KB, Ulrich JT, Redbach JA, McMahon G, Vargas R, et al. : Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: a prospective, double-blind, randomized, controlled trial. Crit Care Med. 1995;23(1):9-17. Epub 1995/01/01. PubMed PMID: 8001393.
32. Astiz ME, Rackow EC, Kim YB, Weil MH: Monophosphoryl lipid A induces tolerance to the lethal hemodynamic effects of endotoxemia. Circ Shock 33(2): 92-97, 1991.
33. Casella CR, Mitchell TC: Inefficient TLR4/MD-2 heterotetramerization by monophosphoryl lipid A. PLoS One 8(4):e62622, 2013.
34. Alving CR, Peachman KK, Rao M, Reed SG: Adjuvants for human vaccines. Curr Opin Immunol 24(3):310-315, 2012.
35. Bowen WS, Minns LA, Johnson DA, Mitchell TC, Hutton MM, Evans JT: Selective TRIF-dependent signaling by a synthetic Toll-like receptor 4 agonist. Sci Signal 5(211):ra13, 2012.
36. Xiong Y, Medvedev AE: Induction of endotoxin tolerance in vivo inhibits activation of IRAK4 and increases negative regulators IRAK-M, SHIP-1, and A20. J Leukoc Biol 90(6):1141-1148, 2011.
37. Varma TK, Toliver-Kinsky TE, Lin CY, Koutrouvelis AP, Nichols JE, Sherwood ER: Cellular mechanisms that cause suppressed gamma interferon secretion in endotoxin-tolerant mice. Infect Immun 69(9):5249-5263, 2001.
38. Salkowski CA, Detore G, Franks A, Falk MC, Vogel SN: Pulmonary and hepatic gene expression following cecal ligation and puncture: monophosphoryl lipid A prophylaxis attenuates sepsis-induced cytokine and chemokine expression and neutrophil infiltration. Infect Immun 66(8):3569-3578, 1998.
39. Biswas SK, Lopez-Collazo E: Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol 30(10):475-487, 2009.
40. Flohe S, Lendemans S, Schade FU, Kreuzfelder E, Waydhas C: Influence of surgical intervention in the immune response of severely injured patients. Intensive Care Med 30(1):96-102, 2004.
41. Cavaillon JM, Adib-Conquy M: Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit Care 10(5):233, 2006.
42. Gahring LC, Daynes RA: Desensitization of animals to the inflammatory effects of ultraviolet radiation is mediated through mechanisms which are distinct from those responsible for endotoxin tolerance. J Immunol 136(8):2868-2874, 1986.
43. Granowitz EV, Porat R, Mier JW, Orencole SF, Kaplanski G, Lynch EA, et al. : Intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells of healthy humans. J Immunol 151(3):1637-1645, 1993.
44. DobrovolskaiaMA, Medvedev AE, Thomas KE, Cuesta N, Toshchakov V, Ren T, Cody MJ, Michalek SM, Rice NR, Vogel SN, et al. : Induction of in vitro reprogramming by Toll-like receptor (TLR)2 and TLR4 agonists in murine macrophages: effects of TLR Bhomotolerance[ versus Bheterotolerance[ on NFkappa B signaling pathway components. J Immunol. 2003;170(1):508-519. Epub 2002/12/24. PubMed PMID: 12496438.
45. Jacinto R, Hartung T, McCall C, Li L: Lipopolysaccharide-and lipoteichoic acidYinduced tolerance and cross-tolerance: distinct alterations in IL-1 receptorYassociated kinase. J Immunol 168(12):6136-6141, 2002.
46. Li CH, Wang JH, Redmond HP: Bacterial lipoprotein-induced self-tolerance and cross-tolerance to LPS are associated with reduced IRAK-1 expression and MyD88-IRAK complex formation. J Leukoc Biol 79(4):867-875, 2006.
47. Hirschfeld M, Ma Y, Weis JH, Vogel SN, Weis JJ: Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine Toll-like receptor 2. J Immunol 165(2):618-622, 2000.
48. Bagchi A, Herrup EA, Warren HS, Trigilio J, Shin HS, Valentine C, Hellman J. MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. J Immunol. 2007;178(2):1164-1171. Epub 2007/01/05. PubMed PMID: 17202381.
49. Sato S, Takeuchi O, Fujita T, Tomizawa H, Takeda K, Akira S: A variety of microbial components induce tolerance to lipopolysaccharide by differentially affecting MyD88-dependent and-independent pathways. Int Immunol 14(7): 783-791, 2002.
50. Guha M, Mackman N: LPS induction of gene expression in human monocytes. Cell Signal 13(2):85-94, 2001.
51. Medvedev AE, Sabroe I, Hasday JD, Vogel SN: Tolerance to microbial TLR ligands: molecular mechanisms and relevance to disease. J Endotoxin Res 12(3):133-150, 2006.
52. Piao W, Song C, Chen H, DiazMA,Wahl LM, Fitzgerald KA, Li L, Medvedev AE. Endotoxin tolerance dysregulates MyD88-and Toll/IL-1R domain-containing adapter inducing IFN-betaYdependent pathways and increases expression of negative regulators of TLR signaling. J Leukoc Biol. 2009;86(4):863-875. Epub 2009/08/07. doi: 10. 1189/jlb. 0309189. PubMed PMID: 19656901; PubMed Central PMCID: PMC2796624.
53. Lawrence T: The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 1(6):a001651, 2009.
54. Kobayashi K, Hernandez LD, Galan JE, Janeway CA Jr, Medzhitov R, Flavell RA: IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110(2):191-202, 2002.
55. Lawrence T, Fong C: The resolution of inflammation: anti-inflammatory roles for NF-kappaB. Int J Biochem Cell Biol 42(4):519-523, 2010.
56. Chen X, El Gazzar M, Yoza BK, McCall CE: The NF-kappaB factor RelB and histone H3 lysine methyltransferase G9a directly interact to generate epigenetic silencing in endotoxin tolerance. J Biol Chem 284(41): 27857-27865, 2009.
57. Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA: Possible new role for NF-kappaB in the resolution of inflammation. Nat Med 7(12): 1291-1297, 2001.
58. Su J, Xie Q, Wilson I, Li L: Differential regulation and role of interleukin-1 receptor associated kinase-M in innate immunity signaling. Cell Signal 19(7): 1596-1601, 2007.
59. Deng H, Maitra U, Morris M, Li L: Molecular mechanism responsible for the priming of macrophage activation. J Biol Chem 288(6):3897-3906, 2013.
60. Foster SL, Hargreaves DC, Medzhitov R: Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 447(7147):972-978, 2007.
61. El Gazzar M, McCall CE: MicroRNAs distinguish translational from transcriptional silencing during endotoxin tolerance. J Biol Chem 285(27): 20940-20951, 2010.
62. Taganov KD, Boldin MP, Chang KJ, Baltimore D: NF-kappaBYdependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A 103(33):12481-12486, 2006.
63. Tili E, Michaille JJ, Cimino A, Costinean S, Dumitru CD, Adair B, et al. : Modulation of miR-155 and miR-125b levels following lipopolysaccharide/ TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol 179(8):5082-5089, 2007.
64. El GazzarM, Yoza BK, Chen X, Garcia BA, Young NL, McCall CE: Chromatinspecific remodeling by HMGB1 and linker histone H1 silences proinflammatory genes during endotoxin tolerance. Mol Cell Biol 29(7):1959-1971, 2009.
65. El Gazzar M, Yoza BK, Chen X, Hu J, Hawkins GA, McCall CE: G9a and HP1 couple histone and DNA methylation to TNFalpha transcription silencing during endotoxin tolerance. J Biol Chem 283(47):32198-32208, 2008.
66. Nakagawa R, Naka T, Tsutsui H, FujimotoM, Kimura A, Abe T, Seki E, Sato S, Takeuchi O, Takeda K, et al. : SOCS-1 participates in negative regulation of LPS responses. Immunity. 2002;17(5):677-687. Epub 2002/11/16. PubMed PMID: 12433373.
67. Liu ZJ, Liu XL, Zhao J, Shi YJ, Yan LN, Chen XF, Li XH, You HB, Xu FL, Gong JP, et al. : The effects of SOCS-1 on liver endotoxin tolerance development induced by a low dose of lipopolysaccharide are related to dampen NF-kappaBYmediated pathway. Dig Liver Dis. 2008;40(7):568-577. Epub 2008/04/02. doi: 10. 1016/j. dld. 2007. 12. 019. PubMed PMID: 18378198.
68. Adib-Conquy M, Adrie C, Moine P, Asehnoune K, Fitting C, Pinsky MR, Dhainaut JF, Cavaillon JM. NF-kappaB expression in mononuclear cells of patients with sepsis resembles that observed in lipopolysaccharide tolerance. Am J Respir Crit Care Med. 2000;162(5):1877-1883. Epub 2000/11/09. PubMed PMID: 11069829.
69. Wolk K, Docke W, von Baehr V, Volk H, Sabat R: Comparison of monocyte functions after LPS-or IL-10Yinduced reorientation: importance in clinical immunoparalysis. Pathobiology 67(5-6):253-256, 1999.
70. Kwissa M, Nakaya HI, Oluoch H, Pulendran B: Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates. Blood 119(9):2044-2055, 2012.
71. Alving CR: Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants. Immunobiology 187(3-5):430-446, 1993.
72. Kaisho T, Akira S: Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 1589(1):1-13, 2002.
73. Kaisho T, Akira S: Regulation of dendritic cell function through Toll-like receptors. Curr Mol Med 3(4):373-385, 2003.
74. Agrawal S, Agrawal A, Doughty B, Gerwitz A, Blenis J, Van Dyke T, Pulendran B. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signalY regulated kinaseYmitogen-activated protein kinase and c-Fos. J Immunol. 2003; 171(10):4984-9. Epub 2003/11/11. PubMed PMID: 14607893.
75. Pantel A, Cheong C, Dandamudi D, Shrestha E, Mehandru S, Brane L, Ruane D, Teixeira A, Bozzacco L, Steinman RM, et al. : A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit TH1 T-cell immunity in vivo. Eur J Immunol. 2012;42(1):101-9. Epub 2011/10/18. doi: 10. 1002/eji. 201141855. PubMed PMID: 22002164; PubMed Central PMCID: PMC3517108.
76. Watanabe S, Inoue J: Intracellular delivery of lipopolysaccharide induces effective TH1-immune responses independent of IL-12. PLoS One 8(7): e68671, 2013.
77. McAleer JP, Vella AT: Understanding how lipopolysaccharide impacts CD4 T-cell immunity. Crit Rev Immunol 28(4):281-299, 2008.
78. Baldridge JR, McGowan P, Evans JT, Cluff C, Mossman S, Johnson D Persing D. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther. 2004;4(7):1129-38. Epub 2004/07/23. doi: 10. 1517/14712598. 4. 7. 1129. PubMed PMID: 15268679.
79. Kundi M: New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 6(2):133-140, 2007.
80. Garcon N, Morel S, Didierlaurent A, Descamps D, Wettendorff M, Van Mechelen M: Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach. BioDrugs 25(4):217-226, 2011.
81. Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T, Dubin G, et al. : Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. 2009;Hum Vaccine 5(5):332-40. Epub 2009/02/18. PubMed PMID: 19221517.
82. Sow PS, Watson-Jones D, Kiviat N, Changalucha J, Mbaye KD, Brown J, Bousso K, Kavishe B, Andreasen A, Toure M, et al: Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-seronegative African girls and young women. J Infect Dis. 2013;207(11):1753-63. Epub 2012/12/18. doi: 10. 1093/infdis/jis619. PubMed PMID: 23242542; PubMed Central PMCID: PMC3636781.
83. Pedersen C, Breindahl M, Aggarwal N, Berglund J, Oroszlan G, Silfverdal SA, Szuts P, O'Mahony M, David MP, Dobbelaere K, et al. : Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls. J Adolesc Health. 2012;50(1):38-46. Epub 2011/12/23. doi: 10. 1016/j. jadohealth. 2011. 10. 009. PubMed PMID: 22188832.
84. Persing DH, Coler RN, Lacy MJ, Johnson DA, Baldridge JR, Hershberg RM, Reed SG. Taking Toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol. 2002;10(Suppl 10):S32YS7. Epub 2002/10/16. PubMed PMID: 12377566.
85. Gandhapudi SK, Chilton PM, Mitchell TC: TRIF is required for TLR4 mediated adjuvant effects on T cell clonal expansion. PLoS One 8(2):e56855, 2013.
86. Oh JZ, Kurche JS, Burchill MA, Kedl RM: TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway. Blood 118(11):3028-3038, 2011.
87. Murphey ED, Lin CY, McGuire RW, Toliver-Kinsky T, Herndon DN, Sherwood ER: Diminished bacterial clearance is associated with decreased IL-12 and interferon-gamma production but a sustained proinflammatory response in a murine model of postseptic immunosuppression. Shock 21(5):415-425, 2004.
88. Gentile LF, Cuenca AG, Efron PA, Ang D, Bihorac A, McKinley BA, Moldawer LL,Moore FA. Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J Trauma Acute Care Surg. 2012;72(6):1491-501. Epub 2012/06/15. doi: 10. 1097/TA. 0b013e318256e000. PubMed PMID: 22695412.
89. Wysocka M, Montaner LJ, Karp CL: Flt3 ligand treatment reverses endotoxin tolerance-related immunoparalysis. J Immunol 174(11):7398-7402, 2005.
90. Dai WJ, Bartens W, Kohler G, Hufnagel M, Kopf M, Brombacher F: Impaired macrophage listericidal and cytokine activities are responsible for the rapid death of Listeria monocytogenesYinfected IFN-gamma receptorYdeficient mice. J Immunol 158(11):5297-5304, 1997.
91. O'Brien DP, Briles DE, Szalai AJ, Tu AH, Sanz I, Nahm MH: Tumor necrosis factor alpha receptor I is important for survival from Streptococcus pneumoniae infections. Infect Immun 67(2):595-601, 1999.
92. Rothe J, Lesslauer W, Lotscher H, Lang Y, Koebel P, Kontgen F, Althage A, Zinkemagel R, Steinmetz M, Bluethmann H. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature. 1993;364(6440):798-802. Epub 1993/08/26. doi: 10. 1038/364798a0. PubMed PMID: 8395024.
93. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB: Interleukin-10 and related cytokines and receptors. Ann Rev Immunol 22:929-979, 2004.
94. RossatoM, Curtale G, Tamassia N, CastellucciM,Mori L, Gasperini S, Mariotti B, De Luca M, Mirolo M, Cassatella MA, et al. : IL-10Yinduced microRNA-187 negatively regulates TNF-alpha, IL-6, and IL-12p40 production in TLR4-stimulated monocytes. Proc Natl Acad Sci U S A. 2012;109(45):E3101YE310. Epub 2012/10/17. doi: 10. 1073/pnas. 1209100109. PubMed PMID: 23071313; PubMed Central PMCID: PMC3494907.
95. Grutz G: New insights into the molecular mechanism of interleukin-10Ymediated immunosuppression. J Leukoc Biol 77(1):3-15, 2005.
96. van der Sluijs KF, van Elden LJ, Nijhuis M, Schuurman R, Pater JM, Florquin S, Goldman M, Jansen HM, Lutter R, van der Poll T. IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J Immunol. 2004;172(12):7603-9. Epub 2004/06/10. PubMed PMID: 15187140.
97. Metzger DW, Salmon SL, Kirimanjeswara G: Differing Effects of IL-10 in Cutaneous and Pulmonary Francisella tularensis LVS Infection. Infect Immun. 2013;81(6):2022-7. Epub 2013/03/27. doi: 10. 1128/IAI. 00024-13. PubMed PMID: 23529615.
98. Murphy ML, Wille U, Villegas EN, Hunter CA, Farrell JP: IL-10 mediates susceptibility to Leishmania donovani infection. Eur J Immunol 31(10): 2848-2856, 2001.
99. Varma TK, Durham M, Murphey ED, CuiW, Huang Z, Lin CY, Toliver-Kinsky T, Sherwood ER. Endotoxin priming improves clearance of Pseudomonas aeruginosa in wild-type and interleukin-10 knockout mice. Infect Immun. 2005;73(11): 7340-7347. Epub 2005/10/22. doi: 10. 1128/IAI. 73. 11. 7340-7347. 2005. PubMed PMID: 16239532; PubMed Central PMCID: PMC1273831.
100. Mason CM, Dobard E, Summer WR, Nelson S: Intraportal lipopolysaccharide suppresses pulmonary antibacterial defense mechanisms. J Infect Dis 176(5): 1293-1302, 1997.
101. Deng M, Scott MJ, Loughran P, Gibson G, Sodhi C, Watkins S, Hackam D, Billiar TR. Lipopolysaccharide clearance, bacterial clearance, and systemic inflammatory responses are regulated by cell type-specific functions of TLR4 during sepsis. J Immunol. 2013;190(10):5152-60. Epub 2013/04/09. doi: 10. 4049/ jimmunol. 1300496. PubMed PMID: 23562812; PubMed Central PMCID: PMC3644895.
102. Murphey ED, Fang G, Varma TK, Sherwood ER: Improved bacterial clearance and decreased mortality can be induced by LPS tolerance and is not dependent upon IFN-gamma. Shock 27(3):289-295, 2007.
103. Lehner MD, Ittner J, Bundschuh DS, van Rooijen N, Wendel A, Hartung T: Improved innate immunity of endotoxin-tolerant mice increases resistance to Salmonella enterica serovar typhimurium infection despite attenuated cytokine response. Infect Immun 69(1):463-471, 2001.
104. Rayhane N, Fitting C, Lortholary O, Dromer F, Cavaillon JM: Administration of endotoxin associated with lipopolysaccharide tolerance protects mice against fungal infection. Infect Immun 68(6):3748-3753, 2000.
105. Murphey ED, Fang G, Sherwood ER: Endotoxin pretreatment improves bacterial clearance and decreases mortality in mice challenged with Staphylococcus aureus. Shock 29(4):512-518, 2008.
106. Wheeler DS, Lahni PM, Denenberg AG, Poynter SE, Wong HR, Cook JA, Zingarelli B. Induction of endotoxin tolerance enhances bacterial clearance and survival in murine polymicrobial sepsis. Shock. 2008;30(3):267-73. Epub 2008/ 01/17. doi: 10. 1097/shk. 0b013e318162c190. PubMed PMID: 18197145; PubMed Central PMCID: PMC2754132.
107. Roquilly A, Broquet A, Jacqueline C, Gautreau L, Segain JP, de Coppet P, Caillon J, Altare F, Josien R, Asehnoune K, et al. : TLR-4 agonist in post-haemorrhage pneumonia: role of dendritic and natural killer cells. Eur Respir J 2013. Epub 2013/01/15. doi: 10. 1183/09031936. 00152612. PubMed PMID: 23314895.
108. Hirano T, Kodama S, Kawano T, Maeda K, Suzuki M: Monophosphoryl lipid A induced innate immune responses via TLR4 to enhance clearance of nontypeable Haemophilus influenzae and Moraxella catarrhalis from the nasopharynx in mice. FEMS Immunol Med Microbiol 63(3):407-417, 2011.
109. Chase JJ, Kubey W, Dulek MH, Holmes CJ, Salit MG, Pearson FC 3rd, Ribi E. Effect of monophosphoryl lipid A on host resistance to bacterial infection. Infect Immun. 1986;53(3):711-2. Epub 1986/09/01. PubMed PMID: 3744562; PubMed Central PMCID: PMC260854.
110. Romero CD, Varma TK, Hobbs JB, Reyes A, Driver B, Sherwood ER: The Toll-like receptor 4 agonist monophosphoryl lipid A augments innate host resistance to systemic bacterial infection. Infect Immun 79(9): 3576-3587, 2011.
111. Baldridge JR, Cluff CW, Evans JT, Lacy MJ, Stephens JR, Brookshire VG,Wang R, Ward JR, Yorgensen YM, Persing DH, et al. : Immunostimulatory activity of aminoalkyl glucosaminide 4-phosphates (AGPs): induction of protective innate immune responses by RC-524 and RC-529. J Endotoxin Res. 2002;8(6):453-8. Epub 2003/04/17. doi: 10. 1179/096805102125001064. PubMed PMID: 12697089.
112. Airhart CL, Rohde HN, Bohach GA, Hovde CJ, Deobald CF, Lee SS, Minnich SA. Induction of innate immunity by lipid A mimetics increases survival from pneumonic plague. Microbiology. 2008;154(Pt 7):2131-8. Epub 2008/07/05. doi: 10. 1099/mic. 0. 2008/017566-0. PubMed PMID: 18599840.
113. Lembo A, Pelletier M, Iyer R, Timko M, Dudda JC, West TE, Wilson CB, Haijar AM, Skerrett SJ. Administration of a synthetic TLR4 agonist protects mice from pneumonic tularemia. J Immunol. 2008;180(11):7574-81. Epub 2008/05/21. PubMed PMID: 18490759; PubMed Central PMCID: PMC3063511.
114. Lehner MD, Hartung T: Endotoxin tolerance-mechanisms and beneficial effects in bacterial infection. Rev Physiol Biochem Pharmacol 144: 95-141, 2002.
115. Hafenrichter DG, Roland CR, Mangino MJ, Flye MW: The Kupffer cell in endotoxin tolerance: mechanisms of protection against lethal endotoxemia. Shock 2(4):251-256, 1994.
116. Ruggiero G, Andreana A, Utili R, Galante D: Enhanced phagocytosis and bactericidal activity of hepatic reticuloendothelial system during endotoxin tolerance. Infect Immun 27(3):798-803, 1980.
117. AstizME, Saha DC, Carpati CM, Rackow EC: Induction of endotoxin tolerance with monophosphoryl lipid A in peritonitis: importance of localized therapy. J Lab Clin Med 123(1):89-93, 1994.